Migrainous
vertigo is a common cause of
dizziness presenting to an otorhinolaryngology/otoneurology clinic. Although it causes a substantial burden to the individual and society there are no randomized controlled trails on prophylactic medication for this condition.
Flunarizine, a
calcium channel blocker has been used effectively in both
migraine and vestibular conditions. This randomized control trial was undertaken in a tertiary academic referral center to evaluate the efficacy of
flunarizine in patients with migrainous
vertigo when compared to non-specific vestibular treatment of
betahistine and vestibular exercises. The effect of
flunarizine on two particularly disabling symptoms of
vertigo and
headache was studied. A total of 48 patients who were diagnosed with definitive migrainous
vertigo completed the study of 12 weeks duration. Patients in arm A received 10-mg
flunarizine daily along with
betahistine 16 mg and
paracetamol 1 gm during episodes, and arm B received only
betahistine and
paracetamol during episodes. Symptom scores were noted at the start of the study and at the end of 12 weeks. Analysis of the frequency of vertiginous episodes showed a significant difference between arm A and arm B (p = 0.010) and improvement in severity of
vertigo between the two groups (p = 0.046).
Headache frequency and severity did not improve to a significant degree in arm A as compared to arm B. The main side effects were
weight gain and
somnolence and this was not significantly different between the two groups.
Flunarizine (10 mg) is effective in patients with migrainous
vertigo who suffer from considerable vestibular symptoms.